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Abstract
Background: A significant proportion of the human genome is comprised of human endogenous retroviruses
(HERVs). HERV transcripts are found in every human tissue. Expression of proviruses of the HERV-K(HML-2)
family has been associated with development of human tumors, in particular germ cell tumors (GCT). Very little
is known about transcriptional activity of individual HML-2 loci in human tissues, though.
Results: By employing private nucleotide differences between loci, we assigned ~1500 HML-2 cDNAs to
individual HML-2 loci, identifying, in total, 23 transcriptionally active HML-2 proviruses. Several loci are active in
various human tissue types. Transcription levels of some HML-2 loci appear higher than those of other loci.
Several HML-2 Rec-encoding loci are expressed in GCT and non-GCT tissues. A provirus on chromosome
22q11.21 appears strongly upregulated in pathologic GCT tissues and may explain high HML-2 Gag protein levels
in GCTs. Presence of Gag and Env antibodies in GCT patients is not correlated with activation of individual loci.
HML-2 proviruses previously reported capable of forming an infectious HML-2 variant are transcriptionally active
in germ cell tissue. Our study furthermore shows that Expressed Sequence Tag (EST) data are insufficient to
describe transcriptional activity of HML-2 and other HERV loci in tissues of interest.
Conclusion: Our, to date, largest-scale study reveals in greater detail expression patterns of individual HML-2
loci in human tissues of clinical interest. Moreover, large-scale, specialized studies are indicated to better
comprehend transcriptional activity and regulation of HERVs. We thus emphasize the need for a specialized HERV
Transcriptome Project.
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The human genome harbors a significant amount of
sequences that stem from retroviral infections of the germ
line in evolutionarily ancient times, so-called human
endogenous retroviruses (HERVs). Repeated (re)infection
by different exogenous retroviruses, and intracellular
amplification of endogenous retroviral sequences, or
composite elements with retroviral portions, resulted in
about 8% of the human genome having a retroviral ori-
gin. A great number of distinct HERV families have been
defined that each stem from germ line infections of dis-
tinct exogenous retroviruses. Many of the integrated retro-
viruses (proviruses) became defective due to
accumulation of nonsense mutations, large internal dele-
tions, or reduction to so-called solitary LTRs after homol-
ogous recombination within a provirus [for reviews, see
[1-4]].
Since proviruses carry their own transcriptional promoters
and regulators within the Long Terminal Repeats (LTRs),
HERV sequences are able to initiate transcription of the
proviral gag, pro, pol and env genes, but also to initiate
transcription of neighboring cellular genes. Splice signals
within HERVs can also result in variant transcripts of cel-
lular genes. Various examples have been well documented
where HERV sequences influence the transcription of cel-
lular genes or alter the structure of cellular transcripts [for
instance, see references [5-11]]. In accord, HERV
sequences display characteristic distributions relative to
genes [12]. It appears that HERV sequences are much
more likely to loose coding-capacity due to nonsense
mutations than they loose their promoter activity. There-
fore, many HERV promoter sequences still display tran-
scriptional activity after millions of years in the genome.
In fact, recent studies demonstrated that there is virtually
no human tissue that lacks HERV transcripts, and tran-
scripts from several HERV families are usually found in
every investigated human tissue [13,14].
The regulation of transcriptionally active HERV sequences
is, as of yet, little understood. While chromatin status
probably contributes to their regulation, CpG methyla-
tion status of HERV promoter and regulatory regions
appears as a crucial factor for activity versus inactivity [15-
17]. However, relatively little is known about transcrip-
tion factors actually regulating transcriptional activity of
individual HERV loci [11].
Expression of HERV sequences has been proposed to be
involved in the etiology of various human diseases. How-
ever, no direct connection could be established in most
cases so far [18,19]. An involvement in human disease has
been shown particularly for the human endogenous retro-
virus family HERV-K(HML-2), in short, HML-2, that is
exceptional for various reasons. While there are a number
of evolutionarily old HML-2 loci in the human genome
[20] evolutionarily young HML-2 loci have been pro-
posed to have formed in the human lineage by reinfection
rather than an intracellular copying mechanism, raising
the possibility that an infectious HML-2 variant is present
in the human population until today [21,22]. An infec-
tious and replication-competent HML-2 variant was
recently engineered from a consensus sequence of evolu-
tionarily young HML-2 loci [23,24]. Recent HML-2 activ-
ity also resulted in a number of HML-2 loci that are
polymorphic in the human population due to incomplete
fixation [25-30].
It is known that HML-2 sequences are drastically upregu-
lated in germ cell tumors (GCT), the most frequent tumor
among young men. The precursor lesion of GCT, the car-
cinoma in situ, already displays strong HML-2 expression
[31]. HML-2 is also exceptional because of its coding
capacity for Gag, Pro, Pol and Env proteins in that several
HML-2 loci in the human genome still encode those pro-
teins [for reviews, see [1,32]]. Gag protein is readily
detectable in GCT tissue and GCT patients display high
antibody titers against HML-2 Gag and Env proteins at the
time of tumor detection [33,34]. Furthermore, some
HML-2 loci encode a functional homologue of the HIVRev
protein, named Rec, that interacts with PLZF (a protein
involved in spermatogenesis in the mouse) and that
results in disturbed spermatogenesis in Rec-transgenic
mice [35,36]. Another HML-2 protein, Np9, is encoded by
some mutated HML-2 loci that lack a 292 bp sequence at
the pol/env boundary, so-called type 1 proviruses, as
opposed to type 2 proviruses. Np9 may be involved in
GCT development as well [37]. Expression of HML-2 RNA
and proteins has also been investigated in more detail in
melanoma [38-40]. The role of HML-2 in both GCT and
melanoma remains to be clarified.
While upregulation of HML-2 in GCT is well documented,
little is known about HML-2 loci actually being activated
in the course of GCT development. Do higher transcript
levels in GCT result from drastic upregulation of only a
few HML-2 loci or from upregulation of a greater number
of loci? What HML-2 loci are expressed in GCT tissue and
in corresponding normal testicular tissue? More generally,
what HML-2 loci are transcriptionally active in various
human tissues? Especially the latter question is legitimate
for all other HERV families as well. In fact, there is very
restricted or no information at all on what specific HERV
loci contribute to the cellular RNA pool in various tissues
and how expression patterns of individual HERV loci vary
between, for instance, healthy and diseased conditions.
Recent analysis employed molecular genetic and bioinfor-
matic means to identify HERV transcripts. First, HERV-
derived cDNAs have been generated and assigned to indi-
vidual HERV loci in smaller scale studies [41-45], andPage 2 of 17
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analysis employed sequence data deposited in the human
section of the Expressed Sequence Tag database dbEST
[47] in order to identify transcriptionally active HML-2
and other HERV loci [48,49]. A number of active loci have
been identified by doing so.
However, we will demonstrate here that sequence data in
dbEST are insufficient for a detailed description of HERV
expression patterns in various cell types and cellular con-
ditions. Yet, given their quantity, a more comprehensive
investigation of the transcriptional activity of HERV loci
appears fundamental for better understanding the tran-
scriptional activity of the human genome as a whole.
Recent results from the pilot phase of the Encyclopedia of
DNA Elements (ENCODE) Project provided both fasci-
nating and provocative insights into the transcriptional
activity of the human genome, especially regarding perva-
sive transcription of the human genome [50-52]. Consid-
ering their inherent promoter activity and their
ubiquitous expression, HERV sequences may be responsi-
ble for a significant number of transcripts.
In the present study, we communicate results from the
largest-scale identification of transcriptionally active
HML-2 loci so far, and their expression patterns in human
tissues of interest. We compare our results to previously
published work by others and us. We conclude that a spe-
cialized, potentially collaborative HERV cDNA sequenc-
ing project, a HERV Transcriptome Project, is needed to
comprehensively describe transcriptional activities of
HERV loci in human normal and diseased tissues.
Results
Generation of HML-2 cDNA sequences
We analyzed, in total, 49 samples derived from tumor and
normal tissues that were of higher interest because of var-
ious previous findings. In detail, we analyzed 15 samples
from testicular tissue including 10 different seminoma
samples and 5 samples from normal or non-malignant
testis. We analyzed 15 brain samples including 5 samples
from normal brains, 5 samples from patients with a bipo-
lar disorder and 5 samples from patients with schizophre-
nia. We analyzed 9 brain tumors of different stages of
malignancy (common type meningiomas, atypical men-
ingioma, meningioma grades II and III, glioblastoma
multiforme). We also analyzed the following samples: a
mammary carcinoma and a normal mammary tissue, a
lung carcinoma and a normal lung tissue, the germ cell
tumor-derived cell line Tera-1 and the mammary carci-
noma-derived cell line T47D.
We performed RT-PCR on RNA isolated from each speci-
men employing HML-2-specific PCR primer pairs that
were located within the central region of the HML-2 gag
gene and the 3' region of the HML-2 env gene, generating
PCR products of about 650 bp and 500 bp, respectively.
In total, forty-seven samples were subjected to a gag-spe-
cific RT-PCR and 30 samples were subjected to an env-spe-
cific RT-PCR. Following RT-PCR, products were cloned
and individual cDNAs were sequenced and assigned to
specific HML-2 proviruses in the human genome based
on private (one or several nucleotides that are characteris-
tic for an HML-2 locus) nucleotide differences between
individual loci depicted in Fig. 1. An in-house Bio-Python
script, LOCUS-ASSIGNER, was employed for that pur-
pose. The script is available from the authors on request.
We generated, in total, 1587 cDNA sequences; 975 for gag
and 612 for env. Among those, 327 cDNAs were generated
from brain tumor samples, 374 cDNAs were generated
from normal brain, and brains with bipolar and schizo-
phrenic condition, and 666 cDNAs were generated from
testicular samples. We generated up to 49 cDNAs for each
tissue specimen, with an average of 30 (SD 13.7) cDNAs
per specimen. We restricted interpretation of results for
specimens with low numbers of generated cDNA
sequences, such as for lung tissue and T47D. Nevertheless,
those data have been included in Additional File 1 for the
sake of completeness. Results for the Tera-1 cell line and
retroviral particles produced by Tera-1 cells will be
described in more detail elsewhere (Ruprecht et al., man-
uscript submitted).
Based on our recently published data [53], we excluded
5.5% of cDNA sequences (6.9% for gag and 3.4% for env)
from the analysis because they very likely represented ex
vivo recombined cDNAs from transcripts from different
HML-2 proviral loci, evidenced by a significantly higher
number of mismatches for the best cDNA-provirus match.
We thus analyzed 1499 cDNA sequences, that is, those
cDNA sequences were assigned to individual HML-2 pro-
viral loci, identifying the particular proviral locus as tran-
scriptionally active in the regarded tissues. The below
given relative cloning frequencies indicate for each HML-
2 locus how often gag or env individual cDNA sequences
generated from a particular tissue sample could be
assigned to a particular locus relative to the total number
of assignable gag or env cDNAs for that tissue sample. For
example, a relative cloning frequency of 20% for locus
c1_A means that 8 out of 40 cDNA clones could be
assigned to c1_A for a given tissue sample. When appro-
priate, results from several tissue samples were combined.
Absolute numbers of transcriptionally active HML-2 loci
indicate how many different loci were represented by the
total number of cDNAs for a given tissue sample.
Transcriptionally active HML-2 proviruses
Overall, our analysis detected 23 transcriptionally active
HML-2 proviruses in the human genome. Twenty-one
proviruses were detected by gag-derived cDNAs and 14Page 3 of 17
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viruses were detected exclusively by gag cDNAs and 2 pro-
viruses were detected exclusively by env cDNAs.
Transcriptionally active HML-2 proviruses were located
on 12 different human chromosomes, with 5 proviruses
being located on human chromosome 3 (Table 1). Results
for all investigated tissue specimens have been summa-
rized in Additional file 1.
As for the structure of transcriptionally active HML-2 pro-
viruses, most of them are intact in that they consist of gag,
pro, pol and env sequences and flanking 5' and 3' LTRs (see
Additional file 2). Based on the presence or absence of a
292 bp sequence within the pol-env boundary, both type 2
(n = 10) and type 1 (n = 10), respectively, HML-2 provi-
ruses are transcriptionally active. The structure of the less
intact loci is as follows (see Table 1 for details on provirus
designations). Provirus c1_A lacks a pol region (~nt 3500–
6300 with respect to the HERV-K(HML-2.HOM) sequence
[54]). Proviruses c3_A and c4_A lack a pol region (~nt
3700–5900). Provirus c10_B lacks the 5'LTR and an
approx. 1.3 kb long env region. Provirus c19_A consists of
only an env-3'LTR portion (~nt 7000-end). Provirus c3_D
lacks the 3' half of pol, the env gene and the 3'LTR. Provirus
c7_B and c7_C consist of gag-pro-pol sequence (~nt 1000–
4900), with provirus c7_C being flanked by an LTR in
opposite orientation. Lack of proviral regions in some
proviruses also explains the above-mentioned exclusive
detection of some proviruses as either gag or env-derived
cDNAs. As for the evolutionary ages of active HML-2 loci,
comparative genomics tracks at the UCSC Genome
Browser [55] show that 18 out of 23 active HML-2 loci are
Neighbor joining (NJ) trees of HERV-K(HML-2) sequences in the proviral reference sequence dataset for gag-derived cDNAsFigure 1
Neighbor joining (NJ) trees of HERV-K(HML-2) sequences in the proviral reference sequence dataset for gag-
derived cDNAs. The NJ-trees depict absolute numbers of nucleotide differences between the various sequences, excluding 
indels for pairwise comparisons, thus demonstrating private nucleotide differences between HML-2 loci. The tree on the right 
depicts a subset of sequences, labeled "modern" in the tree on the left, at higher resolution. Only HML-2 loci having the ampli-
fied gag region were included in the tree. The investigated gag region also includes a 96 bp region that distinguishes evolution-
arily modern HERV-K(HML-2) from evolutionarily old (HERV-K(OLD)) proviruses. An intermediary group between modern 
and old proviruses is evident. For better resolution, a separate NJ tree for the modern HML-2 proviruses is shown at the right. 
For the sake of simplicity, only branches of proviruses identified as transcriptionally active in this study are indicated in the tree, 
other branches are unlabelled. Scale bars represent 5 nt differences in the left tree and 1 nt difference in the right tree.Page 4 of 17
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Table 1: Features of transcriptionally active HERV-K(HML-2) loci identified in this study1.
transcripts ORF
gag env gag env type 
1/2
5' 
LTR
age band location amplicon in 
genome
Hughes '04 
polymorphic
Stauffer 
'04 ESTs
Mayer 
'04 Rec 
ORFs
Lavie 
'05
Buzdin 
'06 
cDNAs
Dewann
ieux '06
c1_A + + 1 + h 1p31.1 1 75616984 75617620 1p31 1p31.1
c1_B + + (+) 1 + h 1q22 1 153869999 153870635 1q22* 1q23.1#
c1_C + 1 + h 1q23.3 1 158928816 158929450
c3_A + + 1 + h 3p25.3 3 9869025 9869661
c3_B + + + 1 + h 3q13.2 3 114232719 114233355 3q13.2* 3q13.2
c3_C + + 2 + h 3q21.2 3 127093452 127094088 3q21.2 3q21.2
c3_D + 2 - h 3q24 3 149766793 149767429
c3_E + + 1 + h 3q27.2 3 186769952 186770588 3q27.2
c4_A + 1 + och 4q32.3 4 166137900 166138546 4q32.1
c5_A + + + 1 + h 5q33.3 5 156024213 156024849 5q33.3
c6_A + + + + 2 + h 6q14.1 6 78490549 78491185 K109 6q14.1 6q14.1 6q14.1 K109
c7_A + + + + 2 + h 7p22.1 7 4604296 4604932 K108 7p22.1 7p22.1 7p22.1 K108
c7_B + - h 7q22.1 7 104179212 104179848 7q22.2#
c7_C + OLD - roch 7q34 7 141100988 141101724
c8_A + 2 + h 8p23.1 8 7350016 7350652 K115 8p23 K115
c10_A + + 2 + ch 10p14 10 6913351 6913990 10p14 10p14 10p14
c10_B + 2 - h 10q24.2 10 101576412 101577048 10q24.2 10q24.2
c11_A + + + 2 + h 11q22.1 11 101072629 101073265 11q22 11q22.1 11q22.1 11q22.1
c11_B + 1 + ch 11q23.3 11 118103837 118104468
c12_A + + + 2 + h 12q14.1 12 57014704 57015340 12q14 12q14 12q14.1 12q14.1 12q14.1
c19_A + - h 19p13.3 19 337322 340413
c21_A + + 2 + h 21q21.1 21 18861736 18862372 21q21.1
c22_A + + + 1 + h 22q11.21 22 17307812 17308448 22q11.21
1 Provirus designations are given in the first column. Each provirus was identified (indicated by "+") by gag- and/or env-derived cDNAs. Presence of ORFs for Gag and Env proteins was deduced 
from proviral sequences as given in the March 2006 version of the human genome sequence at the Human Genome Browser. The Gag ORF in provirus c1_B harbors a premature stop in the 
human genome reference sequence but a full-length ORF allele appears to be the more frequent allele in Caucasians (own unpublished data). Provirus type 1 or 2, based on a 292 bp sequence 
within the pol-env boundary (if the proviral region is present), presence of a 5'LTR. "age" indicates presence of orthologous HML-2 loci in rhesus (r), orang-utan (o), chimpanzee (c) and/or human 
(h) genomes, thus indicating evolutionary ages of loci. The chromosomal band in which the provirus is located, and the nucleotide position of the RT-PCR amplicon amplified during cDNA 
generation are given in the following columns. Locus c7_A is an HERV-K(OLD) provirus. For c19_A the position of the env amplicon is given. We compared our results with other recent 
publications (see text for details and references). Hughes '04 denotes proviruses that were identified as polymorphic in the human population. Stauffer '04 denotes proviruses previously identified 
as transcriptionally active by analysis of EST data. "*" indicates that transcriptionally activity of those proviruses was ambiguous based on EST sequence data. Mayer '04 denotes proviruses with 
ORFs for Rec protein. Lavie '05 denotes proviral 5'LTRs previously examined for promoter activity. Note that the 5'LTR of provirus c10_A displayed very low transcriptional activity in the 
previous study when in Tera-1 cells in transient reporter assays. Buzdin '06 denotes transcribed proviruses identified by means of GREM (see text). "#" indicates that a different chromosomal 
band was given for that locus, but sequence comparisons show that corresponding loci are identical with the loci identified in our study. Dewannieux '06 denotes proviruses reported as capable 
of creating an infectious HML-2 variant by recombination. See the text for above mentioned references. Note that provirus designations in other publications are different. Great care has been 
taken to relate provirus designations mentioned in other studies with proviruses mentioned in this study.
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old. Three loci were specific for human and chimpanzee,
one locus was present in orang-utan, chimpanzee and
human. Notably, provirus c7_C belongs to the evolution-
ary precursor of "modern" HERV-K(HML-2.HOM)
sequences, the so-called HERV-K(OLD) subfamily, as
indicated by a 96 bp insertion within gag [20] and its pres-
ence in rhesus, orang-utan, chimpanzee and human.
Based on the human genome reference sequence as given
in the March 2006 version at the UCSC Human Genome
Browser [55], several of the transcriptionally active HML-
2 proviruses harbor open reading frames (ORFs) for HML-
2 genes previously reported to be associated with GCT and
other tumors. Specifically, 7 transcribed proviruses harbor
gag ORFs and 4 proviruses harbor env ORFs. A previously
published study [42] reported that 7 transcribed provi-
ruses harbor an ORF for the HML-2 Rec protein (see
below). Notably, three proviruses (c6_A, c7_A and c12_A)
harbor ORFs for Gag, Env and Rec (Table 1). According to
gene annotations in the Human Genome Browser, 6 tran-
scribed proviruses are located within gene introns: c1_A:
SLC44A5; c1_C: CD48; c5_A: SGCD; c7_B: LHFPL3; c8_A:
DEFB107; c10_B: ABCC2. All proviruses were located in
antisense orientation with respect to the direction of the
genes' transcription.
HML-2 provirus expression in brain tissues
We next analyzed the transcriptional activity of individual
HML-2 proviruses in the various brain tissue specimens. A
total of 21 HML-2 proviruses were found transcribed in 23
different brain tissue specimens. On average, 7.1 (SD 1.9)
proviruses were found expressed in each sample. There
was no obvious difference between specimens regarding
the number of transcribed proviruses or combinations of
transcribed proviruses. Brain tumor samples displayed, on
average, 6.5 (SD 2.9) transcribed proviruses. Samples
from bipolar and schizophrenic conditions and normal
brain displayed 6.8 (SD 1.1), 8 (SD 1.2) and 7.4 (SD 1.1),
respectively, transcribed proviruses. Transcripts from
about 13 proviruses were detected only rarely, that is,
cDNAs from those loci were identified sporadically. For
instance, proviruses c3_A and c3_D were each represented
by only one out of 654 brain-derived gag and env cDNAs.
Only 4 out of 654 cDNAs could be assigned to provirus
c22_A. On the other side, cDNAs from about 5 proviruses
(c3_B, c3_C, c5_A, c7_B, c7_C) were found in almost
every brain sample. For instance, transcripts from provi-
ruses c3_C and c5_A were found in 22/22 and 20/22,
respectively, brain samples with higher cDNA clone num-
bers (Fig. 2).
A previous study revealed differences in HML-2 transcript
levels in human brain samples by means of a pol-based
HERV-specific microarray that included four slightly dif-
ferent HML-2-specific oligonucleotide probes [56]. Specif-
ically, for some of those oligonucleotide probes several
brain samples displayed significantly stronger HML-2 sig-
nal intensities in microarray experiments than other sam-
ples, suggesting differential expression of (a subgroup of)
HML-2 loci. For the present study cDNA previously gener-
ated from brain samples from healthy donors as well as
bipolar and schizophrenic conditions were selected based
on strong and weak HML-2 signal intensities in that 1 out
of 5 samples for each condition had originally shown sig-
nificantly weaker signal intensities [56]. In total, 16 HML-
2 proviruses were found expressed in those brain samples.
As above, proviruses c3_C and c5_A were expressed at
higher levels than others while transcripts from proviruses
c3_A, c3_D, c7_A and c22_A were found transcribed only
rarely. For the transcriptionally active HML-2 loci detecta-
ble in our study there was no obvious correlation between
expression of specific proviruses and previously observed
signal intensities (Fig. 2). Hence, our results indicate that
differences in signal intensities do not appear to be due to
up- or downregulation of specific HML-2 proviruses in the
studied tissues. Other regulatory mechanisms may
account for such differences.
Taken together, HML-2 expression analysis of brain sam-
ples indicates that quite a number of HML-2 proviruses
are transcriptionally active in the human brain, independ-
ent of a benign or malignant condition. Based on cloning
frequencies, which reflect to some extent relative expres-
sion levels, some HML-2 proviruses obviously contribute
more to the HML-2 specific RNA pool than other provi-
ruses, i.e., they are expressed at higher levels than others.
Also, there is no obvious up- or downregulation of spe-
cific HML-2 proviruses when various conditions are
regarded.
HML-2 provirus expression in breast tissue
HML-2 transcripts were recently reported in normal and
malignant mammary tissue (mamma-CA) [44,57,58]. We
examined transcriptionally active HML-2 proviruses in
mamma-CA samples that were available to us, as well as
commercially available RNA from normal breast tissue.
Based on 24 gag cDNAs pooled from 4 mamma-CA spec-
imens, 21 env cDNAs from one mamma-CA, and 22 gag
cDNAs and 19 env cDNAs from normal breast tissue, we
identified 7 and 11, respectively, transcriptionally active
HML-2 proviruses. In mamma-CA tissue about 71% (17/
24) of gag-derived cDNAs were from provirus c1_B, while
only 18% (2/22) of cDNAs were derived from that provi-
rus in normal breast tissue. For env-derived cDNAs from
c1_B, approx. 59% and 42% were from mamma-CA and
normal breast tissue, respectively. While in mamma-CA
no gag cDNA was derived from provirus c3_C, approx.
27% of gag-derived cDNAs and 10% of env-derived
cDNAs were from that locus in normal breast tissue.Page 6 of 17
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nificantly lower frequencies [see Additional file 1]. Thus,
based on cloning frequencies, besides basic expression of
several HML-2 proviruses, provirus c1_B appears tran-
scribed at somewhat higher levels in both mamma-CA
and normal breast tissue, and provirus c3_C appears tran-
scribed at somewhat higher levels in normal breast tissue.
However, while our data provide an insight into HML-2
proviruses transcriptionally active in breast tissue analysis
of a larger number of cDNAs is required to describe in
greater detail the transcriptional pattern of HML-2 provi-
ruses in normal and malignant breast tissue.
HML-2 provirus expression in germ cell tumors
Because of the apparent association of HML-2 with GCT
we aimed at better understanding expression patterns of
HML-2 proviruses in GCT. We analyzed different semi-
noma samples, and atrophic, orchitic and normal testicu-
lar tissues as control samples. Seminoma tissue samples
were chosen based on antibody titers against HML-2 Gag
and Env proteins in respective tissue donors, measured by
a previously established indirect immunofluorescence
method [34]. Tissue donors either displayed antibodies
against Gag and Env, only Env, or neither Gag nor Env.
Transcriptional activity of HERV-K(HML-2) proviruses in different brain tissuesFigure 2
Transcriptional activity of HERV-K(HML-2) proviruses in different brain tissues. For each provirus, the relative 
cloning frequency of gag-derived cDNAs per tissue specimen that were assignable to the particular provirus are given. Only 
proviruses for which transcripts have been found as cDNA are included. Brain tissue specimens have been grouped in those 
derived from various types of brain tumors (CT: common type meningiomas; AT: atypical meningioma; AOII: meningioma 
grade II; GBM: glioblastoma multiforme; AIII: atypical meningioma grade III) and in those from normal, bipolar and schizo-
phrenic patients. Specimens with previously identified stronger (strong) and weaker (w) HML-2-specific signal intensities in 
microarray experiments (see text) are indicated. See Additional file 1 for more details.Page 7 of 17
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expressed in GCT tissues. Like for brain samples, cloning
frequencies of cDNAs from individual proviruses, thus,
presumably their expression levels, differed (Fig. 3). For
provirus c3_C 15% of all gag and 21% of all env cDNAs
generated from testicular tissues were derived from that
provirus. Provirus c22_A was represented by approx. 20%
of gag and 15% of env cDNAs. 11% of gag cDNAs but no
env cDNAs were derived from provirus c11_B. About 19%
of env cDNAs were derived from provirus c7_A whereas
only 3.5% of gag cDNAs were derived from that locus. The
same was found for provirus c1_B (17% env versus 8%
gag).
While a number of proviruses displayed intermediate
cloning frequencies cDNAs from some other proviruses
were found rather rarely, potentially indicating low-level
expression in the investigated testicular tissues. For
instance, provirus c11_A was only represented by 1 testic-
ular tissue-derived env cDNA, provirus c10_A by 2 gag
cDNAs, and proviruses c12_A and c19_A by 3 env cDNAs
each. Notably, the polymorphic status of provirus c8_A
(also named HERV-K115) in the human population [29]
may explain that only 2 gag cDNAs were found in two dif-
ferent tumor samples. Yet, provirus c8_A appears tran-
scriptionally active, albeit low-level active when present.
On average, 9.9 (SD 1.7) proviruses were found expressed
per seminoma sample, with 8.8 (SD 1,6), 10.7 (SD 1.2)
and 11.5 (SD 0.7) proviruses found in samples from
patients with antibodies against HML-2 Gag and Env,
against Env and without antibodies, respectively. Samples
from 3 normal testis displayed 8.3 (SD 1.5) transcribed
proviruses. An atrophic and an orchitic testis sample dis-
played 14 and 9, respectively, active proviruses. Overall
cDNA numbers for the various tissue samples were alike.
As for the different tumor specimens, slight differences in
the number of identified expressed proviruses did not
appear to be due to expression of specific proviruses in
one or the other tumor tissue (Fig. 3). Based on the
present number of analyzed cDNAs, the different semi-
noma specimens seem to express the same set of HML-2
proviruses.
However, there is one notable difference between semi-
noma and normal testis. While provirus c22_A is found
expressed in all seminoma samples, and in orchitic and
atrophic testis samples, with an average relative cloning
frequency of approx. 22% (range 4.5%–60% for gag
cDNAs; 0%–70% for env cDNAs), no cDNA correspond-
ing to provirus c22_A was found in the three normal testis
samples, despite very similar numbers of analyzed cDNAs
(Fig. 3). Provirus c22_A was also found in Tera-1 cells, but
was rarely found in brain (3/493 cDNAs) and in normal
mammary tissue (1/41 cDNAs). It thus appears that pro-
virus c22_A is not expressed in normal testis or other
investigated tissues, or it is expressed at very low level, but
is activated or drastically upregulated in germ cell tumor
cells (and also in other pathologic circumstances, namely
atrophic and orchitic conditions). The same may be true
for proviruses c11_B and c21_A but overall relative clon-
ing frequencies of cDNAs from those proviruses were
lower making it more likely that corresponding cDNAs
were missed in normal testis.
The presumably upregulated provirus c22_A harbors an
ORF for Gag protein. Its prominent expression may
explain strong Gag production in seminoma cells and in
the Tera-1 cell line [34]. Still, other Gag-encoding HML-2
proviruses probably also contribute to the Gag produc-
tion. Though, activation (or upregulation) of provirus
c22_A or other Gag-encoding loci does not correlate with
presence of antibodies in seminoma patients, as corre-
sponding proviruses are found expressed in tumor sam-
ples from both Gag antibody positive and negative donors
(Fig. 4). Likewise, there is no obvious correlation between
expression of Env-encoding proviruses and presence of
Env antibodies. Apparently, based on transcriptionally
active HML-2 loci identified in our study, activation of
single protein-encoding proviruses does not solely
account for antibody production in GCT patients.
Transcription of Rec expressing loci
Previously published results for the HML-2 encoded Rec
protein point to an involvement of Rec in germ cell tumor
development [35,36]. We therefore also analyzed the cod-
ing capacity of transcribed HML-2 proviruses for Rec.
Recently, we identified HML-2 loci in the human genome
with the potential to encode Rec, based on presence of
required sequence elements and a Rec ORF. Rec mRNAs
from some of the loci were identified in Tera-1 cells, in
synovial cells and in the human EST database [42]. Seven
transcriptionally active HML-2 proviruses (c3_D, c6_A,
c7_A, c10_A, c10_B, c11_A, c12_A) were previously iden-
tified as candidates for Rec protein production (Table 1).
Four of those proviruses (c6_A, c7_A, c11_A, c12_A) were
also found expressed as rec mRNA in Tera-1 and synovial
cells. In the present study, transcription of Rec encoding
proviruses was found both in normal testis and in semi-
noma tissue (Fig. 3). Since most of the Rec encoding loci
are among the low-level expressed HML-2 loci, corre-
sponding cDNAs were detected at low frequencies and not
in all tissue samples. cDNAs from 5 Rec-encoding provi-
ruses (c3_D, c6_A, c7_A, c10_A, c11_A) were also found
in 5 different brain samples, likewise at low frequencies
and not in all tissue samples. There was no obvious
expression of one or several Rec encoding proviruses
exclusively in testicular tumor tissues (Table 1, Additional
file 1). While Rec-encoding HML-2 proviruses are
expressed in testicular tissue, our present data do notPage 8 of 17
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cell tumorigenesis.
Analysis of HML-2 specific human ESTs
We compared our results with data provided in the
human section of dbEST. We performed a BLAST-search in
the human dbEST using a 7537 bp HERV-K(HML-
2.HOM) gag-pro-pol-env region (that basically excluded
the LTRs) as probe sequence, and employing standard
parameters. The search yielded significant hits to, in total,
109 different EST entries. We retrieved those EST entries
and compiled information on source tissues (Fig. 5). In
Transcriptional activity of HERV-K(HML-2) proviruses in different germ cell tissuesFigure 3
Transcriptional activity of HERV-K(HML-2) proviruses in different germ cell tissues. The various germ cell tissue 
specimens have been grouped based on presence of Gag and/or Env antibodies in patients (GC1 – GC8), specimens from 
atrophic and orchitic testis (GC10, GC13) and normal testis (GCK1 – Testis). Relative cloning frequencies for gag-derived 
cDNAs are given. See Table 1 for Gag, Env and Rec coding capacity of individual loci, and Fig. 2 and Additional file 1 for further 
details.Page 9 of 17
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derived from germ cells, 12 were derived from neuronal
tissues, 5 from cancerous tissues, and 19 were derived
from a number of other, normal human tissues. Other
ESTs lacked information on the source tissue. As for ESTs
from germ cell tissue, 16 were derived from "pooled germ
cell tumors", and 1, 2 and 4 ESTs were derived from "germ
cell tumor", "teratocarcinoma" and "testis", respectively.
There were no ESTs from brain tumors among the
retrieved ESTs. For reasons discussed below, we did not
further analyze the proviral origin of the EST sequences.
Discussion
Every human tissue harbors HERV transcripts. While over-
all transcriptional activities of various HERV families have
been studied in more detail, little is known about tran-
scriptional activities of specific HERV loci in benign and
malignant tissues. For instance, are only a few or a greater
number of loci for a given HERV family and tissue tran-
scriptionally active? Is the expression of specific HERV loci
up- and downregulated depending on the cellular condi-
tion? Given the significant amount of HERV sequences in
the human genome a better understanding of the regula-
tion of HERV transcription appears crucial for better
understanding transcriptional regulation in the human
genome as a whole. Besides, alterations in transcriptional
activities of HERV loci may provide important insight into
epigenetic alterations in corresponding genomic regions,
potentially affecting critical cellular genes located in those
regions. In the following, we will also emphasize the need
for larger scale and specialized studies to adequately
address those issues.
No correlation between HML-2 provirus activity and HML-2 Gag and Env antibodies in GCT patientsFigure 4
No correlation between HML-2 provirus activity and HML-2 Gag and Env antibodies in GCT patients. Relative 
cloning frequencies of gag-derived cDNAs from various HML-2 loci in malignant and pathologic testicular tissues are given. 
Only active HML-2 loci have been included. Results for tissue samples (GC1, 5, 6, 14, 15) from patients with antibodies against 
Gag and Env (αGag+/αEnv+) are shown as red bars. Yellow bars denote results for tissue samples (GC4, 8) from patients with 
Env but without Gag antibodies (αGag-/αEnv+). Green bars denote results for control tissue samples (GC3, 9, 11) from 
patients with neither Gag nor Env antibodies (αGag-/αEnv-). Note that none of the HML-2 loci appears exclusively expressed 
in all Gag and/or Env antibody-positive samples but not in antibody-negative control samples.Page 10 of 17
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requisite for better understanding regulation of HERV
transcription. We therefore aimed in the present study to
identify transcriptionally active proviruses of the HERV-
K(HML-2) family that is of importance from an evolu-
tionary and a clinical perspective. The strategy for identi-
fying transcriptionally active HML-2 sequences is
relatively straightforward. Because the various HML-2 loci
in the human genome accumulated random mutations
over time each HML-2 locus harbors private nucleotide
differences (Fig. 1). Thus, cDNAs generated from RNA
transcripts from a particular HML-2 provirus should be
identical in sequence to the original provirus. In practice,
this may not hold true because of RT-PCR errors. Also,
SNPs within HML-2 sequences may introduce differences
when compared to the human reference sequence. Previ-
ous work already indicated SNPs within HML-2 coding
regions [28,59]. However, the best cDNA-provirus
sequence match is still expected to be the correct one if
matches to other proviruses display clearly more differ-
ences. Assignment of HML-2 cDNA is further complicated
by ex vivo recombinations between transcripts from differ-
ent proviruses that inevitably occur during cDNA genera-
tion [53]. In the present study, we chose to exclude cDNA
sequences that displayed 18 or more nt differences to the
best match. While the great majority of cDNAs displayed
between zero and 5 nt differences [53] it is likely that there
was a limited number of recombinant cDNAs among the
cDNAs with less than 18 nt differences. Actually, a SAGE
(serial analysis of gene expression)-like strategy could be
applied to such recombinant cDNAs if it was possible to
unambiguously assign each recombined portion to a par-
ticular provirus. Since HML-2 sequences are relatively sim-
ilar in sequence, proper assignment seems difficult or
impossible, but a SAGE-like strategy may be feasible for
other, evolutionarily older and thus more diverged HERV
families.
Since little is known about transcription of individual
HERV sequences in various human tissues, a greater
number of tissues would be of interest for initial studies.
We investigated in the present study in more detail nor-
mal and pathologic germ cell tissue because of the associ-
ation of HML-2 with GCT [1,32], and brain tissues
because of previous results indicating transcriptional dif-
ferences between tissue samples from patients with neu-
ropsychiatric disorders [56].
Our study identified, in total, 23 different HML-2 provi-
ruses as transcriptionally active in the studied tissues. Sev-
eral HML-2 proviruses appeared transcribed in every
investigated tissue. We stress in this context that our
method is not intended to provide quantitative informa-
tion as to overall transcriptional levels of HML-2
sequences in different tissues but to identify those loci
that are transcriptionally active at all. In any case, among
the transcriptionally active proviruses were structurally
intact, full-length proviruses and proviruses lacking inter-
nal or lateral proviral regions. Both type 1 and type 2 pro-
viruses, differing by a 292 bp sequence within the pol-env
boundary, were found transcribed. Notably, few loci
(c7_C, c10_B, c19_A) lack the 5'LTR as the classical provi-
ral promoter. Hitherto unknown flanking promoters
obviously result in transcription of those HML-2
sequences. Given results from the ENCODE project, spe-
cifically the density of initiators of transcription in the
human genome [51,52], it seems plausible that there are
promoters located nearby. Alternatively, as locus c10_B is
located within a gene intron, rare splicing events might
have produced c10_B-harboring transcripts. For locus
c7_C, located closely downstream from the SSBP1 gene,
read-through events might have produced c7_C-harbor-
ing transcripts.
It is likely that there are more than 23 transcriptionally
active HML-2 proviruses. Oligonucleotides employed for
PCR following the RT step display varying amounts of
mismatches to HML-2 loci in the human genome. Tran-
scriptionally active HML-2 loci tended to have less mis-
matches, however, several seemingly inactive loci
displayed as few mismatches as active loci. One or both
primer regions are missing in some of the HML-2 loci [see
Additional file 3]. Transcripts from some proviruses were
indeed detected only as gag- or env-derived cDNAs. While
Summary of tissue origins of HERV-K(HML-2)-derived ESTs in the human ection of dbESTFigure 5
Summary of tissue origins of HERV-K(HML-2)-
derived ESTs in the human section of dbEST. Informa-
tion on tissue origins was compiled from EST sequence 
entries. Source tissues were combined in appropriate groups. 
Black bars indicate the total number of ESTs per source tis-
sue group. Grey bars further indicate the number of ESTs 
from individual source tissues within a source tissue group. 
Tissue designations are as given in the EST sequence entries. 
Note that some ESTs lacked information on source tissues.Page 11 of 17
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matches to the primers were eventually cloned as cDNA,
it is difficult to decide for other loci whether they were not
expressed or could not be efficiently cloned as cDNA for
technical reasons. In fact, a type 1 provirus on human
chromosome 3, previously termed HERV-K(II), was not
identified in our analysis, despite the fact that it is known
to produce np9 mRNA [[45,60], Kehr et al. unpublished].
Transcripts from that provirus were probably not detected
because of 25% and 20% sequence differences to gag and
env, respectively, reverse primers. In the course of larger
scale studies degenerate oligonucleotides or sets of oligo-
nucleotides representing proviral sequence variants
should be employed.
Another point concerns relative cloning frequencies.
While HML-2 sequences expressed at higher levels are
more likely to be cloned as cDNA, many other HML-2 loci
may be transcribed at much lower levels and thus their
cDNA would only appear when many more cDNA
sequences per tissue sample were analyzed. We observed
such differences between tissues for several HML-2 loci.
Considering current sequencing technologies, it should
be quite feasible to generate significantly more cDNA
sequences per tissue sample in the course of a larger study.
Different splicing efficiencies for HML-2 transcripts may
also affect cloning likelihoods of corresponding proviral
transcripts if, for instance, full-length transcripts are effi-
ciently spliced down to env or rec mRNA, making it less
likely to catch gag portions as cDNA, as opposed to splic-
ing-deficient transcripts. However, besides the fact that
type 1 proviruses lack splice signals present in type 2 pro-
viruses, yet, type 1 transcripts still being spliced [61,62],
there is currently no information about splicing efficien-
cies of transcripts from different HML-2 loci.
Furthermore, the polymorphic nature of several poten-
tially transcriptionally active HML-2 proviruses will result
in lack or potentially reduced amounts of corresponding
transcripts for tissue samples from some human donors.
In fact, six of the proviruses identified in our study (c1_A,
c6_A, c7_A, c8_A, c11_A, c12_A) have been described pol-
ymorphic in the human population. Two of those loci
(c1_A and c8_A) represent presence/absence alleles, the
other alleles are full-length (either tandem or single) pro-
viruses, solitary LTRs and/or (empty) preintegration sites
[26].
Based on cloning frequencies, a limited number of HML-
2 proviruses appear transcribed at higher levels in the
investigated brain and testicular tissues than other provi-
ruses. It is currently not clear whether the former provi-
ruses are also transcribed at higher levels in other human
tissues, potentially even showing ubiquitous expression.
Investigation of other human tissues in the course of a
larger project should clarify that point.
GCTs, especially seminomas, display significantly upregu-
lated HML-2 expression, both on the RNA and protein
level. Variable HML-2 expression was previously also
observed in different human brain samples [56]. On the
assumption that relevant proviruses were not missed in
our analysis, our results indicate that observed differences
in expression levels were not primarily due to drastic
upregulation of single HML-2 proviruses but rather due to
global upregulation of HML-2 transcription. This could be
explained by differential expression of factors involved in
the regulation of HML-2 sequences, such as transcription
factors. Deregulated levels of such factors in GCT cells
could result in the activation of HML-2 sequences. As for
previously observed interindividual differences in HML-2
expression levels [56], such differences have also been
observed in the human population for cellular genes, and
sets of genes appear regulated by hitherto unidentified
elements (gene products) in defined genome regions [63-
66]. If regulators of HML-2 transcription were differen-
tially expressed in humans expression levels of those reg-
ulators could indirectly result in differential HML-2
expression levels.
The Gag-encoding provirus c22_A appears strongly upreg-
ulated in pathologic versus normal testicular tissue, and
may thus contribute to high Gag protein levels in GCT.
However, the results from our study also indicate that
presence of HML-2 Gag and Env antibodies in GCT
patients is not correlated with expression of specific HML-
2 proviruses, as several Gag- and Env-encoding HML-2
proviruses, among them c22_A, are transcriptionally
active in both antibody positive and negative GCT
patients. Generation of autoantibodies is currently little
understood. It has been associated with increased expres-
sion of antigens. Immunogenic antigens, i.e. antigens that
cause a humoral immune response, can also stem from
genes altered by specific mutations including chromo-
some alterations and epigenetic DNA modifications. Like-
wise, spliced gene products can give rise to an immune
response. Posttranslational modifications, such as altered
protein folding and processing, may also result in immu-
nogenic antigens. Finally, normal non-altered antigens
can elicit an autoantibody response when expressed in
specific tissues [for a review, see [67]].
Two research groups [23,24] recently described engi-
neered HML-2 proviral sequences that are replication-
competent and infectious. An additional engineered pro-
viral sequence, consisting of portions of so-called HERV-
K109, HERV-K108 and HERV-K115 proviruses, was
reported to generate an infectious retrovirus as well [24].
The authors argued that recombination between thosePage 12 of 17
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K(HML-2) variant. We note that those three proviruses,
named c6_A, c7_A and c8_A in our study, have been iden-
tified by us as transcriptionally active in germ cell tissue.
For all three proviruses have been described polymorphic
in the human population, only some human individuals
will harbor all three proviruses, though. In any case, for
individuals harboring all three, transcripts from those
proviruses would be present and could serve as substrates
for recombination events when transcripts were reverse
transcribed.
Large-scale cDNA sequencing projects have so far gener-
ated about 8.1 million human expressed sequence tag
(EST) entries http://www.ncbi.nlm.nih.gov/dbEST. HML-
2 provirus-derived ESTs are also found in dbEST. How-
ever, our initial analysis of HML-2 specific ESTs clearly
shows that there is insufficient information in dbEST to
comprehensively describe HML-2 proviral expression pat-
terns. Our initial probing of dbEST with a representative
HML-2 gag-pro-pol-env sequence yielded only 109 signifi-
cant hits. Breaking down those hits to specific tissues
resulted in a maximum of 27 ESTs that were derived from
stem cells, only 23 ESTs were derived from germ cells. It is
likely that several of those 23 ESTs stem from the same
HML-2 proviruses. Considering the usually poor sequence
quality of ESTs, proviral assignment of ESTs may often be
ambiguous. Moreover, HML-2 ESTs stem from very few
source tissues. Indeed, few HML-2 ESTs in dbEST stem
from tissues in which HML-2 is clinically relevant, i.e.
germ cell tumors. Such lack of HML-2 ESTs for other tis-
sues erroneously indicates that HML-2 is not transcribed
in those tissues. Though, more detailed analysis of EST
data does not provide significantly more and better infor-
mation. Stauffer et al. [48] recently reported such a more
detailed analysis of HERV-derived ESTs, among them
HML-2-specific ESTs. They identified 143 non-normal-
ized, non-subtracted ESTs matching the HML-2 family.
About a third of the ESTs could not be assigned unambig-
uously to specific HML-2 proviruses. In total, 8 HML-2
proviruses (and 3 ambiguous ones) were identified as
transcriptionally active. Of those, 2 (or 4 when including
the ambiguous ones) were also identified in our study
(Table 1). In other words, our study detected at least 19
transcriptionally active HML-2 proviruses that were not
identified in the detailed EST study by Stauffer et al. A
more recent analysis by Oja et al. [49] reported about 300
HML-2-specific ESTs. However, it seems clear that 300
HML-2 ESTs are still insufficient to describe HML-2
expression patterns in, for instance, human benign and
malignant tissues, and depending on cellular conditions
and stimuli. It is well conceivable that conclusions for
HML-2-specific ESTs are true for ESTs from other HERV
families as well. One can also predict that (overall much
smaller) non-human EST datasets are likewise insufficient
for studying transcriptional activity of ERVs in other spe-
cies. Thus, EST data are insufficient to describe (H)ERV
transcription.
Buzdin et al. [43] recently reported results from an exper-
imental strategy, named GREM (Genome Repeat Expres-
sion Monitor) that is able to specifically amplify HERV
transcripts. A total of 22 HML-2 proviruses were reported
transcribed in parenchyma and/or seminoma. Of those
proviruses, 16 were also identified in our study (Table 1),
7 and 6 proviruses were found exclusively in our or in the
study of Buzdin et al., respectively. Thus, specialized gen-
eration and analysis of HERV-specific transcripts in the
study of Buzdin et al. likewise identified many more tran-
scriptionally active HML-2 proviruses than the very lim-
ited number of ESTs in dbEST.
We conclude that a specialized HERV transcript sequenc-
ing project, a HERV Transcriptome Project, will be required
to comprehend transcriptional activity of HERVs. Bearing
in mind the proportion of HERV sequences, and recent
findings regarding the extent of transcription in the
human genome, a HERV Transcriptome Project could pro-
vide crucial information for better understanding tran-
scriptional regulation not only of HERVs but also of the
human genome in general. For instance, many of the
HERV sequences could function as transcription initiators
and could thus contribute to the pervasive transcription of
the human genome [51]. Considering previously reported
differences in HERV expression patterns between human
tissues, transcriptional activities of individual HERV pro-
viruses are very likely significantly different between tis-
sues as well. Moreover, a HERV Transcriptome Project
could significantly contribute to a better understanding of
proposed roles of HERV sequences in various human dis-
eases if relevant source tissues were analyzed in greater
detail. From that point of view, it will be important to bet-
ter understand cellular conditions under which HERV
sequences are activated or repressed [for instance, see ref.
[68]].
The current study provides an initial insight into the tran-
scriptional activity of a clinically relevant HERV family in
selected human tissues. We believe that strategies to spe-
cifically generate significantly greater numbers of HERV-
specific cDNAs from human tissues and selected cellular
conditions can be established in a straightforward fash-
ion. Current sequencing technologies can produce signif-
icant amounts of HERV cDNA sequences in a short time
that can then be used to identify transcriptionally active
HERV loci. We furthermore believe that a HERV Transcrip-
tome Project would best be pursued in a collaborative
fashion, that is, the project should be open to researchers
proposing analysis of specific HERV families for tissues or
cellular conditions of specific interest.Page 13 of 17
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By assigning ~1500 HML-2 cDNA sequences to individual
genomic loci we showed that a considerable number of
HERV-K(HML-2) loci is transcribed in the investigated
human tissues. Some loci appear transcribed at higher lev-
els than others and some loci are active in several tissue
types. As for the involvement of HML-2 in GCT, our
results point to a provirus on human chromosome
22q11.21 being activated in pathologic germ cell tissue
that may significantly contribute to observed high Gag
protein levels in GCT cells. However, antibodies against
HML-2 Gag and Env in GCT patients do not appear to
result from activation of specific HML-2 loci. Other mech-
anisms seem to trigger HML-2-specific immune
responses. As HML-2 Rec-encoding loci are active in non-
GCT tissues, sole expression of Rec in GCT cells is not the
main reason for its potential involvement in GCT devel-
opment. EST data generated to date are clearly insufficient
to describe in greater detail transcriptional activities of
HML-2 and other HERVs in human tissues and cell types.
Our analysis thus also illustrates that larger-scale analysis
will be essential to comprehensively describe transcrip-
tional activities of individual HERV loci. Considering the
amount of HERV sequences in the human genome, and
ERV sequences in other genomes, studying the contribu-
tion of (H)ERVs to species' transcriptomes is vital to better
comprehend transcription in genomes in general. A spe-
cialized (H)ERV Transcriptome Project is needed.
Materials and methods
Tissue samples
Tissue samples from tumors (brain, breast, lung, testis)
and orchitic and atrophic testis were obtained from surgi-
cal procedures. Tumor tissue specimens from testicular
cancer were obtained from previously untreated patients.
Following orchiectomy, tissue samples were dissected
from macroscopically supposed tumor lesions, snap fro-
zen, and stored at -80°C. Only samples containing >80%
tumor cells were included in the study. Tissues were
obtained with informed consent of patients according to
the Declaration of Helsinki. Postmortem brain tissue sam-
ples were obtained from the Stanley Foundation Brain
Collection (Bethesda, MD, USA) [69]. RNA from normal
testis and breast tissue was obtained from Stratagene Inc.
Germ cell tumor-derived cell line Tera-1 and mammary
carcinoma cell line T47D were cultured in DMEM and
RPMI-1640, respectively, media supplemented with 10%
fetal calf serum in a humidified 5% CO2 atmosphere.
cDNA generation and sequencing
RNA was isolated using Trizol (Invitrogen), following the
manufacturer's recommendation. RNA was subsequently
treated with DNase I (Roche) to remove residual traces of
genomic DNA. Complete removal of DNA was verified by
an Alu element-specific PCR [70]. DNA-free RNA was
used for subsequent cDNA generation, employing the
Omniscript RT Kit (Qiagen) and random hexanucleotide
primers following the manufacturer's recommendations.
For each cDNA preparation control reactions without
reverse transcriptase were included. Subsequent PCR
employed the following HERV-K(HML-2) specific primers
to generate gag and env gene-derived PCR products:
gag_plus (5'GGCCATCAGAGTCTAAACCACG3'; nt
1626–1647 in HERV-K(HML-2.HOM); Genbank acces-
sion number AF074086); gag_minus
(5'GCAGCCCTATTTCTTCGGACC3'; nt 2242–2262);
env8146F (5'AATGAGTCTGAGCATCACTGGG3'; nt
8146–8167), and env8665R
(5'CCATTCAACTCTGAGTGGACACAG3'; nt 8665–
8688). The PCR mix consisted of 0.5 μM of each PCR
primer; 1.5 mM MgCl2; 0.2 mM dNTPs; 2.5 units Taq
polymerase (Invitrogen); 1 × PCR buffer in a total volume
of 50 μl. PCR cycling conditions were as follows: initial
denaturation 5 min. 94°C; 40 cycles 1 min. 94°C; 45 sec.
57°C; 1 min. 72°C; final elongation 10 min. 72°C. Gen-
eration of cDNA from brain tissues from normal, bipolar
and schizophrenic conditions was described previously
[56]. RT-PCR products were subsequently purified using
spin prep columns (PeqLab), ligated into the pGEM T-
Easy vector (Promega) and transformed into DH5α or
TOP10F' bacterial cells. Insert-containing clones were
identified by standard colony-PCR using above primer
combinations. Plasmid DNA of positive clones was iso-
lated using a standard column procedure (QIAprep Spin
Miniprep Kit; Qiagen). Sequences of cloned cDNAs were
obtained using vector-specific sequencing primers and an
Applied Biosystems 3730 × Capillary Sequencer (Institut
für Immunologie und Genetik, Kaiserslautern, Germany).
Quality of sequences was assessed using CodonCode
Aligner (CodonCode Corporation, Dedham, MA, USA)
and FinchTV (Geospiza Inc., Seattle, WA, USA) and cor-
rected if necessary. Poor quality sequence reads were
excluded.
cDNA sequence assignment to proviral loci
Sequences of HML-2 proviral loci, including remnants of
proviral loci, were collected from the human genome
sequence as given at the Human Genome Browser March
2006 version [55] by using the HERV-K(HML-2.HOM)
sequence [54] as probe for BLAT searches [71]. Matching
sequence portions plus flanking sequences were retrieved,
aligned using DiAlign [72] and MAFFT [73] and the align-
ment was manually optimized using Se-Al http://
tree.bio.ed.ac.uk/software/seal. Gag and env subregions
were extracted from the alignment and used as reference
sequences for further analysis. Locus-Assigner is an in-
house Bio-Python script for assigning experimental HERV
cDNA sequences to HERV reference sequences. The script
is available from the authors on request. The strategy of
assigning cDNA sequences to specific proviruses was
based on private nucleotide differences between the vari-
ous HML-2 sequences (Fig. 1). Private means one or sev-Page 14 of 17
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locus when compared to all other loci. Ideally, a cDNA
will be identical to the corresponding proviral sequence
that generated the original transcript, but dissimilar to all
other proviral loci. Locus-Assigner uses as input an exper-
imental cDNA sequence file and a reference sequence file
and generates all possible pairs of experimental cDNA
sequences and reference sequences that are saved as indi-
vidual fasta files. Locus-Assigner then generates pairwise
sequence alignments for each cDNA sequence/reference
sequence pair using CLUSTAL W. Pairwise alignments are
saved as separate files. For each of those files, the total
amount of nt differences between the aligned pair of
sequences is calculated. Mismatches due to start and end
gaps were ignored, as some cDNA and reference
sequences lacked portions at the 5' or 3' end. For each
experimental sequence Locus-Assigner then creates a tab-
separated file summarizing detected nucleotide differ-
ences compared to all reference sequences. Using appro-
priate software, nt differences can be sorted, thus revealing
for each cDNA sequence the most closely related reference
locus, that is, the provirus that most likely generated the
original transcript. The Locus-Assigner script was verified
with a number of test sequences that were run against the
HML-2 reference sequence dataset. Test sequences either
derived from genomic HML-2 sequences or from cDNA
sequences with known amounts of nt differences, 5', 3',
and/or internal gaps. Locus-Assigner results were further
verified by comparison with results from probing test
sequences by BLAT at the UCSC Human Genome
Browser, by visual inspection of alignments and by check-
ing several of the Locus-Assigner cDNA/HML-2 locus
assignments. cDNA sequences with 18 or more mis-
matches with their best matching reference sequence were
excluded from further analysis because they very likely
represent recombined cDNAs from different proviral tran-
scripts that arose ex vivo during cDNA generation [53].
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